| Literature DB >> 31397353 |
Guo-Ping Song1, Ting-Ting Yao1, Dan Wang1, Yue-Hua Li1.
Abstract
Diffusion kurtosis imaging can be used to assess pathophysiological changes in tissue structure and to diagnose central nervous system diseases. However, its sensitivity in assessing hippocampal differences between patients with Alzheimer's disease and those with amnestic mild cognitive impairment has not been characterized. Here, we examined 20 individuals with Alzheimer's disease (11 men and 9 women, mean 73.2 ± 4.49 years), 20 with amnestic mild cognitive impairment (10 men and 10 women, mean 71.55 ± 4.77 years), and 20 normal controls (11 men and 9 women, mean 70.45 ± 5.04 years). We conducted diffusion kurtosis imaging, using a 3.0 T magnetic resonance scanner, to compare hippocampal differences among the three groups. The results demonstrated that the right hippocampal volume and bilateral mean kurtosis were remarkably smaller in individuals with Alzheimer's disease compared with those with amnestic mild cognitive impairment and normal controls. Further, the mean kurtosis was lower in the amnestic mild cognitive impairment group compared with the normal control group. The mean diffusion in the left hippocampus was lower in the Alzheimer's disease group than in the amnestic mild cognitive impairment and normal control groups, while the mean diffusion in the right hippocampus was lower in the Alzheimer's disease group than in the normal control group. Fractional anisotropy was similar among the three groups. These results verify that bilateral mean kurtosis and mean diffusion are sensitive to the diagnosis of Alzheimer's disease and amnestic mild cognitive impairment. This study was approved by the Ethics Review Board of Affiliated Sixth People's Hospital of Shanghai Jiao Tong University, China on May 4, 2010 (approval No. 2010(C)-6).Entities:
Keywords: zzm321990Alzheimer's disease; amnestic mild cognitive impairment; diffusion kurtosis imaging; fractional anisotropy; hippocampus; magnetic resonance imaging; mean diffusion; mean kurtosis; nerve regeneration; neural regeneration
Year: 2019 PMID: 31397353 PMCID: PMC6788254 DOI: 10.4103/1673-5374.262594
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
Differences in age, sex, years of education, and MMSE scores among the NC, aMCI, and AD groups
| Item | NC | aMCI | AD |
|---|---|---|---|
| Age (year) | 70.45±5.04 | 71.55±4.77 | 73.2±4.49 |
| Sex ratio (male: female) | 1.22 | 1 | 1.22 |
| Years of education | 8.24±3.84 | 6.06±4.14 | 9.54±6.75 |
| MMSE score | 29.22±0.97 | 26.85±1. 42* | 21.15 ±1.23*# |
Data are expressed as the mean ± SD (n = 20; one-way analysis of variance and Fisher test). *P < 0.05, vs. NC group; #P < 0.05, vs. aMCI group. MMSE: Mini-mental state examination; NC: normal control; aMCI: amnestic mild cognitive impairment; AD: Alzheimer’s disease.
STROBE Statement—checklist of items that should be included in reports of observational studies
| Item No | Recommendation | Page | |
|---|---|---|---|
| 1 | ( | 1 | |
| ( | 1 | ||
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 1-2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 2 |
| Study design | 4 | Present key elements of study design early in the paper | 2 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 2 |
| Participants | 6 | ( | 2 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 3 |
| Bias | 9 | Describe any efforts to address potential sources of bias | |
| Study size | 10 | Explain how the study size was arrived at | 4 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 6 |
| Statistical methods | 12 | ( | 6 |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 4 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 4 |
| Outcome data | 15* | 4 | |
| Main results | 16 | ( | 4- 6 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 4- 6 |
| Key results | 18 | Summarise key results with reference to study objectives | 9 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 9 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 10 |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 1 |
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Normalized hippocampal volumes (cm3) among aMCI, AD, and NC groups
| NC | aMCI | AD | |
|---|---|---|---|
| Right hippocampus | 2.74±0.38 | 2.61±0.35 | 2.10±0.32# |
| Left hippocampus | 2.62±0.51 | 2.35±0.47 | 2.05±0.45 |
Data are expressed as the mean ± SD (n = 20; one-way analysis of variance followed by Fisher’s least significant difference test). #P < 0.05, vs. aMCI group. NC: Normal control; aMCI: amnestic mild cognitive impairment; AD: Alzheimer’s disease.
Mean kurtosis, mean diffusion, and fractional anisotropy values in the bilateral hippocampi among the NC, aMCI, and AD groups
| NC | aMCI | AD | |
|---|---|---|---|
| Mean kurtosis | |||
| Right hippocampus | 0.81±0.20 | 0.70±0.09* | 0.59±0.10*# |
| Left hippocampus | 0.79±0.08 | 0.69±0.09 | 0.61±0.14*# |
| Mean diffusion | |||
| Right hippocampus | 1.34±0.30 | 1.47±0.20 | 1.60±0.18* |
| Left hippocampus | 1.13±0.26 | 1.14±0.29 | 1.36±0.35*# |
| Fractional anisotropy | |||
| Right hippocampus | 0.17±0.05 | 0.17±0.03 | 0.16±0.02 |
| Left hippocampus | 0.18±0.05 | 0.17±0.04 | 0.16±0.03 |
Data are expressed as the mean ± SD (n = 20; analysis of variance followed by the Fisher’s least significant difference test). *P < 0.05, vs. NC group; #P < 0.05, vs. aMCI group. NC: Normal control; aMCI: amnestic mild cognitive impairment; AD: Alzheimer’s disease.